Head-to-head evidence
HMS1005 vs PB-201
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
HMS1005
Developed by Hua Medicine
NCT06498284 · Phase 1 · completed
The trial randomized participants against a matched placebo with both participants and investigators blinded, but the primary measures were safety and drug levels rather than a validated diabetes outcome like HbA1c. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The sponsor release does not cite the trial's registry number; identity rests on the matching sponsor, drug code, country, design and enrollment.
PB-201
Developed by PegBio
NCT05102149 · Phase 3 · status unknown
This is a randomized, fully blinded trial with both an active and a placebo comparator, testing a recognized clinical measure (HbA1c) in a reasonably large group of patients, but no results are available yet to confirm whether PB-201 met its goal.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HMS1005's landscape · PB-201's landscape